Patients undergoing Anaesthesia
Conditions
Interventions
Trade Name: Rocuronium Bromide (Esmeron)
Product Name: Esmeron
Product Code: 05003/0041
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Rocuronium Bromide
Concentration unit: mg/ml mi
Sponsors
Royal Group Hospitals
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ASA class I-III aged 18-65 scheduled to undergo elective surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Pregnancy Taking medication known to interact with neuromuscular blocking drugs Known or suspected anaphylaxis to any of the study medications Suspected difficult intubation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To find the dose of rocuronium that provides conditions equal to those encountered when using suxamethonium whilst performing a rapid sequence induction;Secondary Objective: Are there any safety issues associated with the dose of rocuronium which provides equal intubating conditions to those of suxamethonium;Primary end point(s): The primary outcome to be measured is the ‘intubation Conditions score’. We wish to demonstrate which dose of rocuronium provides intubating conditions equal to those with suxamethonium in 9/10 subjects | — |
Countries
United Kingdom
Outcome results
None listed